Posted inClinical Updates Dermatology Oncology
Low-Dose Intralesional Cemiplimab Shows Promising Efficacy in Early-Stage Cutaneous Squamous Cell Carcinoma: Insights from a Phase 1 Dose-Escalation Study
A phase 1 study demonstrates that low-dose intralesional cemiplimab is safe and achieves high complete response rates in early-stage cutaneous squamous cell carcinoma, supporting further clinical exploration.